GLP-1 Eye Issues: What UK Patients Should Know (October 2026)

01 · The core answer

Are GLP-1 eye issues relevant to you?

They are relevant to you if you are taking, or considering, a GLP-1 medicine and you notice any change in your vision, or you already have an eye condition.

A sudden, dramatic change in vision is always a reason to get medical help straight away, whatever medicine you take. That includes a sudden loss of sight in one eye, a dark patch or curtain in your field of vision, or a sudden blur that does not clear. Do not message a pharmacy and wait. Get medical help straight away from an urgent NHS service, an emergency eye service or A&E, and tell the clinician which medicines you use.

Second, a slow or mild blur, tired eyes or dryness has many everyday explanations. These include screen use, a change in glasses prescription, dry-eye problems and, in people with diabetes, changes in blood sugar. A prescriber or optician can sort out which applies. Please do not self-diagnose from a forum thread.

02 · Your next step

What to do next, depending on your situation

If you are not yet on treatment, mention any eye history in your consultation. That covers diabetic eye disease, glaucoma, previous optic nerve problems and any recent change in vision. A GPhC-registered prescriber reviews every consultation, and what you tell them shapes whether treatment is suitable. You can read about the weight loss clinic and how treatment works before you decide.

If you are already on Mounjaro and have a new symptom that is not sudden, book an optician or GP appointment and let your prescribing team know. If the symptom is sudden, get medical help straight away and tell us afterwards. You can also report it through the Yellow Card scheme.¹⁹

Related guide: Mounjaro and eye issues.

03 · What the evidence says

What is known about eye problems and Mounjaro

The authoritative place to check what a UK medicine can cause is its Summary of Product Characteristics and the patient information leaflet. For Mounjaro these are the SmPC and the leaflet on the electronic medicines compendium.¹¹³

Eye problems such as sudden vision loss are not listed as a side effect in the UK patient leaflet, and blurred vision is not on the leaflet list either. Tell your prescriber about any new or lasting symptom. If you have a symptom, it still deserves proper assessment. Whether or not a symptom is linked to a medicine, it can be a sign of something that needs treatment in its own right.

If you want more detail on specific questions, see our guides on GLP-1 eye side effects and on Mounjaro and eyesight.

Your prescriber, your optician and the leaflet in your pen box are better placed to answer questions about your own eyes and your own history.

04 · Sudden vision loss

Sudden vision loss and NAION: what to do

Sudden vision loss is the one eye symptom to act on immediately: get medical help straight away. What matters in practice is how you respond to the symptom.

The warning signs people ask about are changes in vision that arrive suddenly rather than creeping in. These include a loss of sight in part or all of one eye, a dark or missing area in your vision, or a sudden blur. If you notice any of these, get medical help straight away; do not wait to see whether it improves overnight. Go to an emergency eye service or A&E. Take your medicine list with you, and mention that you use a GLP-1 medicine such as Mounjaro.

Do not stop or change a prescribed medicine on your own because of an online article. Do tell the prescribing team about the event as soon as you are safe and assessed, so that it can be recorded and the right decision about ongoing treatment can be made with you. You can also report a suspected side effect through the Yellow Card scheme.¹⁹ Reports help regulators spot patterns that no single pharmacy can see.

05 · Blurred vision

Blurred vision: does it go away, and how long does it last?

Blurred vision is not on the list of side effects in the UK patient leaflet, so tell your prescriber about any new or lasting symptom and have it checked by an optician.¹³

Blurring has a long list of everyday causes unrelated to any medicine. Prolonged screen use, tired or dry eyes, an out-of-date glasses prescription and poor sleep can all contribute. For people with diabetes, changes in blood sugar can affect how clearly you see. It is sensible to rule these out with an optician before assuming a medicine is responsible.

Some practical steps are reasonable for mild, gradual symptoms. Book a sight test and tell the optician which medicines you take. Keep a short note of when the blur occurs, such as after meals, in the evening or when reading. Mention it at your next monthly review, which is part of our aftercare. A pattern helps a clinician far more than a general description.

What we would not do is wait indefinitely. If blurring is getting worse, is not improving, or comes with pain, redness, flashing lights or floaters you have not had before, move it up the queue and be seen promptly. And if it arrives suddenly, get medical help straight away.

Blurred vision is common and usually has a benign explanation, but the cases that are not benign are the ones where delay costs the most. An optician sight test is a low-effort way to find out which group you are in.

06 · Existing eye conditions

If you already have an eye condition or diabetes

If you have an existing eye condition, tell your prescriber before you start, and keep your regular eye appointments throughout treatment. Our consultation is free, reviewed by a GPhC-registered prescriber, and designed to find out exactly this sort of thing.

Why does it matter? Your eye history is part of the full picture a prescriber weighs up when deciding whether a medicine is appropriate for you. A GLP-1 medicine changes appetite and how quickly the stomach empties, and for people with diabetes it can also change blood sugar control.¹³ Where blood sugar and the eyes are connected, your whole care team should know what is happening.

People with diabetes should be especially clear about this. Let the screening service and your diabetes team know about any new treatment. If you use insulin or sulfonylureas, your doses may need adjusting because of the risk of low blood sugar. Your diabetes team can guide you on that.

For people without diabetes but with other eye conditions, such as glaucoma or a past optic nerve problem, the same principle applies. Give the prescriber the diagnosis, the name of your eye clinic and any medicines you take for your eyes. They can then decide whether treatment is suitable or whether your eye specialist should be asked first.

Finally, if you are unsure what counts as relevant, say it anyway. A short mention that turns out to be unimportant costs nothing, whereas an omitted detail may matter a great deal.

07 · How Mounjaro works

How Mounjaro works, and why that is not the whole eye story

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes. It comes as a pre-filled multi-dose pen, called a KwikPen, in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Tirzepatide activates two natural gut-hormone receptors at once, GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin. In practice most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹ That dual action distinguishes it from single-action GLP-1 medicines such as semaglutide, found in Wegovy and Ozempic.

Medicines in the class differ, and what applies to one product does not automatically apply to another.

What the mechanism does tell you is why the medicine is used alongside a reduced-calorie diet and increased physical activity, and why individual results vary.²

Your decision should rest on suitability for you, your prescriber's advice and the product information for each medicine, and not on a headline about the class as a whole.

08 · Reporting side effects

Reporting a suspected eye side effect

Report any suspected side effect through the MHRA Yellow Card scheme, whether or not you are sure the medicine is the cause.¹⁹ You do not need to prove a link. The scheme exists because regulators can only spot rare problems when many individual reports are pooled, and you can submit a report yourself without going through a clinician.

When you report, include what you noticed, when it began, which medicine and dose you use, and any other medicines or conditions. If an eye specialist has examined you, note their findings. The more precise the report, the more useful it is. Mention the report to your prescribing team too, since our aftercare includes side-effect support.

What we can do is take your report seriously, review whether continuing is appropriate, and make sure you are directed to the right clinician. If you ever feel a symptom is being dismissed, ask for it to be recorded and escalate it.

The Yellow Card scheme also covers counterfeit medicine alerts.⁷ That matters here, because medicines bought from unregulated sellers do not come with the same assurance about what is in the pen. If you notice an unexpected symptom after using a product from a seller offering to supply without a consultation or prescription, tell a clinician exactly what you used and report it.

Reporting is not an admission of anything and will not affect your treatment or your standing with us. It is simply how the safety picture for every medicine gets built over time.

09 · Stopping and aftercare

Stopping treatment, clearance and monthly reviews

If you and a clinician decide to stop Mounjaro because of a symptom, the medicine does not leave your system immediately. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear.¹ There is no way to speed this up, and nothing needs doing while it clears. This is worth knowing, because a symptom that continues for a short time after the last injection does not mean stopping failed.

That said, never assume a medicine is the cause and stop without advice if your symptom is sudden. Get medical help straight away first. Then discuss with the prescriber whether to pause, continue or change treatment. Decisions about restarting should be made with the clinician who knows your eye findings.

Our aftercare is built around this kind of conversation. It includes ongoing monthly reviews, dose titration and follow-up assessments by the prescribing team, plus side-effect support. Repeat orders re-check suitability, and nothing is auto-shipped, so there is a natural point to flag a new symptom before the next pen is dispensed. Support is available Monday to Friday, 9am to 5pm, by email at support@everydaymeds.co.uk, through the account portal chat or by phone on 0333 207 0413.

Our free companion app, GLPTrackr, lets you log how you feel alongside your doses. A simple record of when a symptom began, relative to injections, is the sort of detail a clinician appreciates.

In short, the sensible order of events for a worrying symptom is: get assessed, tell your prescriber, decide together what to do with your treatment, and report via Yellow Card.¹⁹

10 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

11 · NHS and private routes

NHS and private treatment: the same eye-safety rules apply

Whichever route you use to obtain Mounjaro, the same product information applies and the same advice about eye symptoms holds. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition. The NHS primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

On the NHS, your GP or specialist service already holds your records, including any eye history and hospital eye clinic letters. With a private pharmacy, you are the one who must bring that information to the consultation. That is why we ask you to declare eye conditions up front, and why you should mention treatment from either route to your optician.

If you choose a private provider, check that it is properly registered. Ours is a GPhC-registered pharmacy, registration 9012878, and you can verify it on the GPhC register. Supply comes through official LillyDirect channels, meaning Mounjaro direct from Eli Lilly's UK distribution, with genuine KwikPens.

If you want to understand how treatment fits with wider health, our guides to GLP-1 and heart issues and Mounjaro and stroke follow the same careful approach.